It is called Sensyo Pharmatech SA. A new entity created by the Swedish company Recipharm, three Moroccan banks, the Mohammed VI Investment Fund and the Moroccan Samir Machour, constitutes a new step in the process of establishing vaccine manufacturing capacities in Morocco.
With the effective involvement of the Swedish company Recipharm as well as a consortium of three large national banking groups and especially the Mohammed VI Investment Fund and the Moroccan Samir Machour, the project to establish vaccine manufacturing capacities in Morocco has just passed to the last straight line with the creation of the company “Sensyo Pharmatech SA”.
Due to see the light of day before the end of 2021, the project for the first center of excellence for filling injectable anti-Covid vaccines by parenteral route in Africa has just entered a new stage in its realization.
Before long, the Sinopharm coronavirus vaccine manufacturing project was further strengthened with the involvement of the Mohammed VI Investment Fund, the Swedish laboratory Recipharm as well as that of a banking consortium made up of BMCE Bank of Africa, Banque Centrale Populaire and Attijariwafa Wafa Bank as well as the Senior Vice-President & chief Quality Officer of Samsung Biologics in South Korea, Samir Machour.
After having created the company MaroccoSino Pharma last March, the three large banks of Morocco proceeded to change its corporate purpose and its name on September 1, thus becoming BAB consortium SA The latter, with its enlarged and modified corporate purpose, may set up industrial projects, carry out all commercial or industrial operations related to drugs, but also take stakes in any existing or new company.
Thus, together with the Mohammed VI Investment Fund, they created the Swedish company and Samir Machour the company Sensyo Pharmatech SA.
Sensyo Pharmatech SA, the future leading vaccine manufacturer in Africa
Regarding this, the Competition Council announced yesterday that it had received notification concerning the creation of a company under the name “Sensyo Pharmatech SA” by the Mohammed VI Investment Fund, three Moroccan banks (BMCE Bank in Africa, Banque Centrale Populaire and Attijariwafa bank Wafa Bank), the company Recipharm AB and the Moroccan Samir Machhour.
According to the press release, this company will be active “In the biotechnology sector and the fill & finish industry for vaccine production”.
The aforementioned parties intend, according to a communication from the Competition Council, to create a company whose purpose is to establish a factory in the form of a manufacturing organization, the purpose of which is to distribute activities for the production of vaccines and biotechnology products.
Recipharm AB, a Swedish company operating in the pharmaceutical field, will support the Moroccan side in the construction of this factory, forming work teams in Morocco and Europe in its factories, and working on the transfer of expertise and knowledge to ensure the required quality.
The result of a public-private partnership, this project, which plans to start in the short term, with a monthly production capacity of 5 million doses of anti-Covid19 vaccines per month, has started to begin on schedule.
Lamia Tazi’s insurance
The CEO of the Sothema group, Lamia Tazi, previously told MoroccoLatestNews that “The date scheduled for the launch of vaccine manufacturing is maintained until now”.
Tazi clarified that “All regulatory procedures are continuing and nothing has changed regarding the process”.
In July, King Mohammed VI chaired at the Royal Palace in Fez, the ceremony for the launching and signing of conventions relating to the project of manufacturing and syringing in Morocco the anti-Covid19 vaccine and other vaccines.
This is a historic project launched by the Sovereign which will allow the Kingdom to acquire vaccine sovereignty, important in these times of pandemic, and which is also part of the King’s desire to endow the Kingdom of complete and integrated industrial and biotechnological capacities, dedicated to the manufacture of vaccines in Morocco.
The result of a public-private partnership, the project aims to start in the short term with a production capacity of 5 million doses of anti-Covid-19 vaccine per month, before gradually increasing this capacity in the medium term. It will mobilize a global investment of around $ 500 million.
Thus, the aim of the project is the production in our country of the anti-Covid vaccine, as well as other key vaccines, so as to promote the self-sufficiency of the Kingdom and make Morocco a leading biotechnology platform at the scale from the African continent and the world in the field of the “fill & finish” industry.